These results show that treatment with Tra may reverse the expression of Smyd3 and Shcbp1, which could serve as a good therapeutic drug for breast cancer patients with high levels of Smyd3-Shcbp1 signaling. Here, SHCBP1 is linked to breast carcinoma.